You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Core Diagnostics will exclusively offer GenePeeks' preconception screen and advanced analytics platform in 29 states and seven territories in India.
The new deal, which covers Greece and Cyrus, follows a series of partnerships with fertility organizations and a separate distribution pact signed earlier this year.
The multiplexed PCR kit will target mutations associated with cystic fibrosis that are highly prevalent in the US, and the firm is also eyeing the Middle East and Africa.
Natera has entered the oncology space with a ctDNA assay and sees its blood banking service as a way to eventually tap into the consumer genomics space.
Natera ran 17 percent more tests in Q2 than it did in the prior-year period, generating $53.6 million in total revenues.
Quest's QHerit will screen for 22 disorders and is based on recommendations issued this year by the American College of Obstetricians and Gynecologists.
Under an agreement, Angsana's network of physicians in Hong Kong will be able to order Counsyl's expanded carrier screening test.
Over the next month the company plans to expand its preconception screening test, which it launched widely earlier this year, by adding about 90 X-linked disorders.
Last year, GenePeeks raised $16 million in a Series B funding round from 5AM Ventures, Columbus Nova Technology Partners, Alexandria Venture Investments, Alta Partners, and others.
The company announced the new product, which covers variants across 600 genes, this week, and said it will be available to customers next month.
European regulators have begun a rolling review of Russia's Sputnik V SARS-CoV-2 vaccine, Reuters reports.
Science reports that Science Foundation Ireland is seeking annual budget increases.
According to the Financial Times, a UK university group is pushing Elsevier to lower its journal fees.
In Nature this week: satellite tracking and genome sequencing combination used to examine migration patterns of peregrine falcons, and more.